Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 105

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 105
---
 blockers on survival in patients with advanced      
 non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. Journal of Cancer Research 
 and Clinical Oncology. 2009;135(10):1429–1435. doi:10.1007/s00432-009-0589-1                             |

Clinical Background and Unmet Need

The global anticancer therapeutics market is undergoing
rapid growth, driven by the rising incidence of cancer and advancements in treatment technologies. According to The Brainy Insights, the
market was valued at approximately $222.71 billion in 2023 and is projected to reach around $885.44 billion by 2033, reflecting a compound
annual growth rate (CAGR) of 14.80% from 2024 to 2033.

The Nano-Candesartan platform has broad potential
applicability across multiple cancer indications. Although preclinical studies have demonstrated activity in various tumor models, our
initial clinical development will focus on Pancreatic Ductal Adenocarcinoma (PDAC) as the first indication in which efficacy will be
evaluated in humans.

PDAC is a highly aggressive malignancy with
extremely limited treatment options and a very poor prognosis. Current standard therapies offer only modest survival benefits, and there
remains a significant unmet need for more effective and better-tolerated treatments. PDAC remains one of the deadliest malignancies with
a 5-year survival rate under 11% [1]. The current standard of care for advanced PDAC includes combination chemotherapy with Gemcitabine
(Gemzar®) and Nab-Paclitaxel (Abraxane®), and provides only a limited survival benefit. Angiotensin receptor blockers (ARBs),
including generic candesartan, have shown preliminary promise as modulators of the tumor microenvironment. Based on these findings, it
is hypothesized that ARBs may have the potential to enhance the clinical outcomes of anti-cancer therapies, especially such deadly cancer
as pancreatic.

Our novel formulation of liposomal ARB, Nano-Candesartan,
is being developed as a potential combination therapy with standard-of-care agents such as Gemcitabine (Gemzar®) and Nab-Paclitaxel
(Abraxane®). The objective of this approach is to explore whether modulation of the tumor microenvironment could improve tumor penetration
and potentially reduce systemic risks such as blood pressure lowering. Preclinical data suggest Nano-ARB may also influence cancer-associated
fib